Nucleic acid amplification technology for hepatitis B virus, and its role in blood donation screening in blood banks

Saudi Medical Journal

Volumn 30, Issue 11, 2009, Pages 1416-1421

  Bamaga, Mohammad S ^a   Azahar, Essam I ^b   Al Ghamdi, Ahmed K ^b   Al Enzi, Faris Q ^c   Farahat, Fayssal M ^a  

^a AL HADA ARMED FORCES HOSPITAL   (Saudi Arabia)

^b KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^c KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B ANTIBODY; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; VIRUS DNA;

ARTICLE; BLOOD ANALYSIS; BLOOD BANK; BLOOD DONOR; BLOOD SAMPLING; CONTROLLED STUDY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; NONHUMAN; NUCLEIC ACID AMPLIFICATION; POLYMERASE CHAIN REACTION; SAUDI ARABIA; SCREENING TEST; SENSITIVITY AND SPECIFICITY; SEROLOGY; VIRUS DETECTION; VIRUS INFECTIVITY; VIRUS LOAD;

BLOOD BANKS; BLOOD DONORS; DISEASE TRANSMISSION, INFECTIOUS; DNA, VIRAL; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B CORE ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; MASS SCREENING; NUCLEIC ACID AMPLIFICATION TECHNIQUES; POLYMERASE CHAIN REACTION; REPRODUCIBILITY OF RESULTS; SAUDI ARABIA; SENSITIVITY AND SPECIFICITY;

EID: 70449671393     PISSN: 03795284     EISSN: 16583175     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. André F. Hepatitis B epidemiology in Asia, the Middle East and Africa. Vaccine 2000; 18: S20-S22. (Pubitemid 30100458)
2. Ramia S, El-Zaatari M, Sharara AI, Ramlawi F, Farhat B. Current prevalence of hepatitis delta virus (HDV) infection and the range of HDV genotypes in Lebanon. Epidemiol Infect 2007; 135: 959-962. (Pubitemid 47616477)
3. Pillonel J, Saura C, Couroucé AM. Surveillance report; Screening of viral markers for HIV HBV and HCV infections in blood donors in France and residual risk of viral transmission by blood transfusion. Eurosurveillance 1998; 3: 7. [Updated 1998 July, accessed 2009 September 4]. Available from URL: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=115
4. Allain JP. Occult hepatitis B virus infection. Transfus Clin Biol 2004; 11: 18-25.
5. Allain JP. Occult hepatitis B virus infection: implications in transfusion. Vox Sang 2004; 86: 83-91. (Pubitemid 38436885)
6. Brojer E, Grabarczyk P, Liszewski G, Mikulska M, Allain JP, Letowska M, et al. Characterization of HBV DNA+/HBsAg-blood donors in Poland identified by triplex NAT. Hepatology 2006; 44: 1666-1674.
7. Candotti D, Grabarczyk P, Ghiazza P, Roig R, Casamitjana N, Iudicone P, et al. Characterization of occult hepatitis B virus from blood donors carrying genotype A2 or genotype D strains. J Hepatol 2008; 49: 537-547.
8. Chevrier MC, St-Louis M, Perreault J, Caron B, Castilloux C, Laroche J, et al. Detection and characterization of hepatitis B virus of anti-hepatitis B core antigen-reactive blood donors in Quebec with an in-house nucleic acid testing assay. Transfusion 2007; 47: 1794-1802.
9. Yoshikawa A, Gotanda Y, Minegishi K, Taira R, Hino S, Tadokoro K, et al. Lengths of hepatitis B viremia and antigenemia in blood donors: preliminary evidence of occult (hepatitis B surface antigen-negative) infection in the acute stage. Transfusion 2007; 47: 1162-1171.
10. Liu CJ, Chen DS, Chen PJ. Epidemiology of HBV infection in Asian blood donors: emphasis on occult HBV infection and the role of NAT. J Clin Virol 2006; 36: S33-S44.
11. Chaudhuri V, Tayal R, Nayak B, Acharya SK, Panda SK. Occult hepatitis B virus infection in chronic liver disease: full-length genome and analysis of mutant surface promoter. Gastroenterology 2004; 127: 1356-1371.
12. El Khouri M, dos Santos VA. Hepatitis B: epidemiological, immunological, and serological considerations emphasizing mutation. Rev Hosp Clin Fac Med Sao Paulo 2004; 59: 216-224.
13. Kannangai R, Molmenti E, Arrazola L, Klein A, Choti M, Thomas DL, et al. Occult hepatitis B viral DNA in liver carcinomas from a region with a low prevalence of chronic hepatitis B infection. J Viral Hepat 2004; 11: 297-301.
14. Tabor E. Infections by hepatitis B surface antigen gene mutants in Europe and North America. J Med Virol 2006; 78: S43-S47.
15. Youssef A, Yano Y, Utsumi T, abd El-alah EM, abd El-Hameed Ael-E, Serwah Ael-H, et al. Molecular epidemiological study of hepatitis viruses in Ismailia, Egypt Intervirology 2009; 52: 123-131.
16. Koppelman MH, Sjerps MC, Reesink HW, Cuypers HT. Evaluation of COBAS AmpliPrep nucleic acid extraction in conjunction with COBAS AmpliScreen HBV DNA, HCV RNA and HIV-1 RNA amplification and detection. Vox Sang 2005; 89: 193-200.
17. Li L, Chen PJ, Chen MH, Chak KF, Lin KS, Tsai SJ. A pilot study for screening blood donors in Taiwan by nucleic acid amplification technology: detecting occult hepatitis B virus infections and closing the serologic window period for hepatitis C virus. Transfusion 2008; 48: 1198-11206.
18. Bamaga MS, Bokhari FF, Aboud AM, Al-Malki M, Alenzi FQ. Nucleic acid amplification technology screening for hepatitis C virus and human immunodeficiency virus for blood donations. Saudi Med J 2006; 27: 781-787. (Pubitemid 44121925)
19. Allain JP, Reesink HW, Lucey C. A European perspective on the management of donors and units testing positive for hepatitis B virus DNA. Transfusion 2006; 46: 1256-1258. (Pubitemid 44139502)
20. Brotman B, Prince AM. Occurrence of AUSAB test positivity unrelated to prior exposure to hepatitis B virus. J Infect Dis 1984; 150: 714-720. (Pubitemid 15200080)
21. Borkent-Raven BA, Janssen MP, van der Poel CL, de Wit GA, Bonsel GJ, van Hout BA. Cost-effectiveness of additional hepatitis B virus nucleic acid testing of individual donations or minipools of six donations in the Netherlands. Transfusion 2009; 49: 311-319.
22. Velati C, Romanò L, Fomiatti L, Baruffi L, Zanetti AR; SIMTI Research Group. Impact of nucleic acid testing for hepatitis B virus, hepatitis C virus, and human immunodeficiency virus on the safety of blood supply in Italy: a 6-year survey. Transfusion 2008; 48: 2205-2213.
23. Busch MP, Kleinman SH, Jackson B, Stramer SL, Hewlett I, Preston S. Committee report. Nucleic acid amplification testing of blood donors for transfusion-transmitted infectious diseases: Report of the Interorganizational Task Force on Nucleic Acid Amplification Testing of Blood Donors. Transfusion 2000; 40: 143-159.
24. Niederhauser C, Mansouri Taleghani B, Graziani M, Stolz M, Tinguely C, Schneider P. Blood donor screening: how to decrease the risk of transfusion-transmitted hepatitis B virus? Swiss Med Wkly 2008; 138: 134-141.
25. Thaikruea L, Nantachit N, Leetrakool N, Fongsatitkul L, Sompan P, Heaton A, et al. Assessment of a self-deferral form for screening blood donors, Chiang Mai University Hospital, Thailand. Southeast Asian J Trop Med Public Health 2008; 39: 906-912.
26. Ong SC, Lim SG, Li SC. How big is the financial burden of hepatitis B to society? A cost-of-illness study of hepatitis B infection in Singapore. J Viral Hepat 2009; 16: 53-63.
27. El-Zayadi AR, Ibrahim EH, Badran HM, Saeid A, Moneib NA, Shemis MA, et al. Anti-HBc screening in Egyptian blood donors reduces the risk of hepatitis B virus transmission. Transfus Med 2008; 18: 55-61. (Pubitemid 351239313)
28. Jardim RN, Gonçales NS, Pereira JS, Fais VC, Gonçales Junior FL. Occult hepatitis B virus infection in immunocompromised patients. Braz J Infect Dis 2008; 12: 300-305.
29. Manzini P, Girotto M, Borsotti R, Giachino O, Guaschino R, Lanteri M, et al. Italian blood donors with anti-HBc and occult hepatitis B virus infection. Haematologica 2007; 92: 1664-1670.
30. Said ZN, El-Sayed MH, El-Bishbishi IA, El-Fouhil DF, Abdel-Rheem SE, El-Abedin MZ, et al. High prevalence of occult hepatitis B in hepatitis C-infected Egyptian children with haematological disorders and malignancies. Liver Int 2009; 29: 518-524.
31. Kleinman SH, Kuhns MC, Todd DS, Glynn SA, McNamara A, DiMarco A, et al. Frequency of HBV DNA detection in US blood donors testing positive for the presence of anti-HBc: implications for transfusion transmission and donor screening. Transfusion 2003; 43: 696-704. (Pubitemid 36629113)